Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Unlike other companies grappling with evolving trade policy, Pfizer didn't revise its full-year outlook Tuesday.

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

Pfizer Inc. (NYSE: PFE) chief executive Albert Bourla says uncertainty related to higher tariffs on pharmaceutical imports ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

Goldman Sachs keeps Neutral on Pfizer, citing unclear product growth plans and focus on M&A amid changing market valuations ...

CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on ...

Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Pfizer is raising the bar for its sweeping cost-savings drive yet again, this time cranking up the total target to $7.7 ...

Like his Big Pharma peers, Pfizer (PFE) CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on pharmaceutical imports. To be sure ...